New Dual-Action drug targets Hard-to-Treat kidney cancer
NCT ID NCT06649682
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage study tests a new drug called NYM096 in people with advanced clear cell kidney cancer that has spread. The study has two parts: first, using a low dose to see if it can light up tumors on scans, and second, giving higher doses to see if it can shrink tumors and find the safest dose. About 20 participants will be enrolled, and the main goal is to check safety and side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CLEAR CELL RENAL CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Peking Union Medical College Hospital
Beijing, Beijing Municipality, 100730, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a pill rewrite the genetic story of resistant kidney cancer?
- Can a Two-Pronged immune attack shrink kidney tumors before surgery?
- Can a rapid drug switch outsmart advanced kidney cancer?
- Can a tracer that hunts unstable iron light up hidden tumors?
- Can a pill that starves tumors of oxygen help fight advanced cancer?
- New imaging agent aims to spot Hard-to-Find kidney cancer spread